APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cardiovascular Drug Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cardiovascular Drug Therapy Market Outlook and Growth Opportunities 2026

Report ID 173975170422 December 2025216 pages

Choose your research edition.

Industry ResearchCardiovascular Drug Therapy Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Cardiovascular Drug Therapy Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Cardiovascular Drug Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cardiovascular Drug Therapy Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Cardiovascular Drug Therapy Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Cardiovascular Drug Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cardiovascular Drug Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cardiovascular Drug Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cardiovascular Drug Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cardiovascular Drug Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cardiovascular Drug Therapy market include Zhejiang Huahai Pharmaceutical, Takeda, Sanofi, Johnson & Johnson, Qilu pharmaceutical, Novartis, Merck, Eli Lilly and Gilead, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Cardiovascular Drug Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cardiovascular Drug Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cardiovascular Drug Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cardiovascular Drug Therapy market.

Cardiovascular Drug Therapy Segment by Company

Zhejiang Huahai Pharmaceutical

Takeda

Sanofi

Johnson & Johnson

Qilu pharmaceutical

Novartis

Merck

Eli Lilly

Gilead

Pfizer

Daiichi Sankyo

Bayer

Bristol-Myers

Amgen

AstraZeneca

United Therapeutics

Tasly Holding Group

Lepu Medical

CSPC Pharmaceutical

CHIA TAI TIANQING

Boehringer Ingelheim

Cardiovascular Drug Therapy Segment by Type

Oral Medication

Injection

Cardiovascular Drug Therapy Segment by Application

Hospital

Retail

Cardiovascular Drug Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cardiovascular Drug Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Cardiovascular Drug Therapy key companies, revenue, market share, and recent developments.

3. To split the Cardiovascular Drug Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Cardiovascular Drug Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cardiovascular Drug Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Cardiovascular Drug Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cardiovascular Drug Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cardiovascular Drug Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cardiovascular Drug Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cardiovascular Drug Therapy industry.

Chapter 3: Detailed analysis of Cardiovascular Drug Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Cardiovascular Drug Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Cardiovascular Drug Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cardiovascular Drug Therapy Industry Trends Table 2. Cardiovascular Drug Therapy Industry Drivers Table 3. Cardiovascular Drug Therapy Industry Opportunities and Challenges Table 4. Cardiovascular Drug Therapy Industry Restraints Table 5. Global Cardiovascular Drug Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cardiovascular Drug Therapy Revenue Share by Company (2021-2026) Table 7. Global Cardiovascular Drug Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Cardiovascular Drug Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Cardiovascular Drug Therapy Company, Product Type & Application Table 10. Global Cardiovascular Drug Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Cardiovascular Drug Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oral Medication Table 15. Significant Companies of Injection Table 16. Global Cardiovascular Drug Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Cardiovascular Drug Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Cardiovascular Drug Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Cardiovascular Drug Therapy Sales Value Share by Type (2021-2026) Table 20. Global Cardiovascular Drug Therapy Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Retail Table 23. Global Cardiovascular Drug Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Cardiovascular Drug Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Cardiovascular Drug Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Cardiovascular Drug Therapy Sales Value Share by Application (2021-2026) Table 27. Global Cardiovascular Drug Therapy Sales Value Share by Application (2027-2032) Table 28. Global Cardiovascular Drug Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Cardiovascular Drug Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Cardiovascular Drug Therapy Sales Value Share by Region (2021-2026) Table 31. Global Cardiovascular Drug Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Cardiovascular Drug Therapy Sales Value Share by Region (2027-2032) Table 33. Global Cardiovascular Drug Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Cardiovascular Drug Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Cardiovascular Drug Therapy Sales Value Market Share by Country (2021-2026) Table 36. Global Cardiovascular Drug Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Cardiovascular Drug Therapy Sales Value Market Share by Country (2027-2032) Table 38. Zhejiang Huahai Pharmaceutical Company Information Table 39. Zhejiang Huahai Pharmaceutical Business Overview Table 40. Zhejiang Huahai Pharmaceutical Cardiovascular Drug Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Zhejiang Huahai Pharmaceutical Cardiovascular Drug Therapy Product Portfolio Table 42. Zhejiang Huahai Pharmaceutical Recent Development Table 43. Takeda Company Information Table 44. Takeda Business Overview Table 45. Takeda Cardiovascular Drug Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Takeda Cardiovascular Drug Therapy Product Portfolio Table 47. Takeda Recent Development Table 48. Sanofi Company Information Table 49. Sanofi Business Overview Table 50. Sanofi Cardiovascular Drug Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Sanofi Cardiovascular Drug Therapy Product Portfolio Table 52. Sanofi Recent Development Table 53. Johnson & Johnson Company Information Table 54. Johnson & Johnson Business Overview Table 55. Johnson & Johnson Cardiovascular Drug Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Johnson & Johnson Cardiovascular Drug Therapy Product Portfolio Table 57. Johnson & Johnson Recent Development Table 58. Qilu pharmaceutical Company Information Table 59. Qilu pharmaceutical Business Overview Table 60. Qilu pharmaceutical Cardiovascular Drug Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Qilu pharmaceutical Cardiovascular Drug Therapy Product Portfolio Table 62. Qilu pharmaceutical Recent Development Table 63. Novartis Company Information Table 64. Novartis Business Overview Table 65. Novartis Cardiovascular Drug Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Novartis Cardiovascular Drug Therapy Product Portfolio Table 67. Novartis Recent Development Table 68. Merck Company Information Table 69. Merck Business Overview Table 70. Merck Cardiovascular Drug Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Merck Cardiovascular Drug Therapy Product Portfolio Table 72. Merck Recent Development Table 73. Eli Lilly Company Information Table 74. Eli Lilly Business Overview Table 75. Eli Lilly Cardiovascular Drug Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Eli Lilly Cardiovascular Drug Therapy Product Portfolio Table 77. Eli Lilly Recent Development Table 78. Gilead Company Information Table 79. Gilead Business Overview Table 80. Gilead Cardiovascular Drug Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Gilead Cardiovascular Drug Therapy Product Portfolio Table 82. Gilead Recent Development Table 83. Pfizer Company Information Table 84. Pfizer Business Overview Table 85. Pfizer Cardiovascular Drug Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Pfizer Cardiovascular Drug Therapy Product Portfolio Table 87. Pfizer Recent Development Table 88. Daiichi Sankyo Company Information Table 89. Daiichi Sankyo Business Overview Table 90. Daiichi Sankyo Cardiovascular Drug Therapy Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Daiichi Sankyo Cardiovascular Drug Therapy Product Portfolio Table 92. Daiichi Sankyo Recent Development Table 93. Bayer Company Information Table 94. Bayer Business Overview Table 95. Bayer Cardiovascular Drug Therapy Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Bayer Cardiovascular Drug Therapy Product Portfolio Table 97. Bayer Recent Development Table 98. Bristol-Myers Company Information Table 99. Bristol-Myers Business Overview Table 100. Bristol-Myers Cardiovascular Drug Therapy Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Bristol-Myers Cardiovascular Drug Therapy Product Portfolio Table 102. Bristol-Myers Recent Development Table 103. Amgen Company Information Table 104. Amgen Business Overview Table 105. Amgen Cardiovascular Drug Therapy Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Amgen Cardiovascular Drug Therapy Product Portfolio Table 107. Amgen Recent Development Table 108. AstraZeneca Company Information Table 109. AstraZeneca Business Overview Table 110. AstraZeneca Cardiovascular Drug Therapy Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. AstraZeneca Cardiovascular Drug Therapy Product Portfolio Table 112. AstraZeneca Recent Development Table 113. United Therapeutics Company Information Table 114. United Therapeutics Business Overview Table 115. United Therapeutics Cardiovascular Drug Therapy Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. United Therapeutics Cardiovascular Drug Therapy Product Portfolio Table 117. United Therapeutics Recent Development Table 118. Tasly Holding Group Company Information Table 119. Tasly Holding Group Business Overview Table 120. Tasly Holding Group Cardiovascular Drug Therapy Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Tasly Holding Group Cardiovascular Drug Therapy Product Portfolio Table 122. Tasly Holding Group Recent Development Table 123. Lepu Medical Company Information Table 124. Lepu Medical Business Overview Table 125. Lepu Medical Cardiovascular Drug Therapy Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Lepu Medical Cardiovascular Drug Therapy Product Portfolio Table 127. Lepu Medical Recent Development Table 128. CSPC Pharmaceutical Company Information Table 129. CSPC Pharmaceutical Business Overview Table 130. CSPC Pharmaceutical Cardiovascular Drug Therapy Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. CSPC Pharmaceutical Cardiovascular Drug Therapy Product Portfolio Table 132. CSPC Pharmaceutical Recent Development Table 133. CHIA TAI TIANQING Company Information Table 134. CHIA TAI TIANQING Business Overview Table 135. CHIA TAI TIANQING Cardiovascular Drug Therapy Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. CHIA TAI TIANQING Cardiovascular Drug Therapy Product Portfolio Table 137. CHIA TAI TIANQING Recent Development Table 138. Boehringer Ingelheim Company Information Table 139. Boehringer Ingelheim Business Overview Table 140. Boehringer Ingelheim Cardiovascular Drug Therapy Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 141. Boehringer Ingelheim Cardiovascular Drug Therapy Product Portfolio Table 142. Boehringer Ingelheim Recent Development Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Cardiovascular Drug Therapy Product Image Figure 2. Global Cardiovascular Drug Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cardiovascular Drug Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Cardiovascular Drug Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oral Medication Image Figure 8. Injection Image Figure 9. Global Cardiovascular Drug Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Cardiovascular Drug Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Cardiovascular Drug Therapy Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Retail Image Figure 14. Global Cardiovascular Drug Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Cardiovascular Drug Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Cardiovascular Drug Therapy Sales Value Share by Application (2021-2032) Figure 17. Global Cardiovascular Drug Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Cardiovascular Drug Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Cardiovascular Drug Therapy Sales Value (2021-2032) & (US$ Million) Figure 20. North America Cardiovascular Drug Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Cardiovascular Drug Therapy Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Cardiovascular Drug Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Cardiovascular Drug Therapy Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Cardiovascular Drug Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Cardiovascular Drug Therapy Sales Value (2021-2032) & (US$ Million) Figure 26. South America Cardiovascular Drug Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Cardiovascular Drug Therapy Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Cardiovascular Drug Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Medication
  • Injection
Applications
  • Hospital
  • Retail
Companies covered
  • Zhejiang Huahai Pharmaceutical
  • Takeda
  • Sanofi
  • Johnson & Johnson
  • Qilu pharmaceutical
  • Novartis
  • Merck
  • Eli Lilly
  • Gilead
  • Pfizer
  • Daiichi Sankyo
  • Bayer
  • Bristol-Myers
  • Amgen
  • AstraZeneca
  • United Therapeutics
  • Tasly Holding Group
  • Lepu Medical
  • CSPC Pharmaceutical
  • CHIA TAI TIANQING
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cardiovascular Drug Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cardiovascular Drug Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Cardiovascular Drug Therapy Market Dynamics
  1. 2.1 Cardiovascular Drug Therapy Industry Trends
  2. 2.2 Cardiovascular Drug Therapy Industry Drivers
  3. 2.3 Cardiovascular Drug Therapy Industry Opportunities and Challenges
  4. 2.4 Cardiovascular Drug Therapy Industry Restraints
3 Cardiovascular Drug Therapy Market by Company
  1. 3.1 Global Cardiovascular Drug Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Cardiovascular Drug Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Cardiovascular Drug Therapy Company Ranking (2024-2026)
  4. 3.4 Global Cardiovascular Drug Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Cardiovascular Drug Therapy Company Product Type and Application
  6. 3.6 Global Cardiovascular Drug Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Cardiovascular Drug Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Cardiovascular Drug Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Cardiovascular Drug Therapy Market by Type
  1. 4.1 Cardiovascular Drug Therapy Type Introduction
  2. 4.1.1 Oral Medication
  3. 4.1.2 Injection
  4. 4.2 Global Cardiovascular Drug Therapy Sales Value by Type
  5. 4.2.1 Global Cardiovascular Drug Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Cardiovascular Drug Therapy Sales Value by Type (2021-2032)
  7. 4.2.3 Global Cardiovascular Drug Therapy Sales Value Share by Type (2021-2032)
5 Cardiovascular Drug Therapy Market by Application
  1. 5.1 Cardiovascular Drug Therapy Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail
  4. 5.2 Global Cardiovascular Drug Therapy Sales Value by Application
  5. 5.2.1 Global Cardiovascular Drug Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Cardiovascular Drug Therapy Sales Value by Application (2021-2032)
  7. 5.2.3 Global Cardiovascular Drug Therapy Sales Value Share by Application (2021-2032)
6 Cardiovascular Drug Therapy Regional Value Analysis
  1. 6.1 Global Cardiovascular Drug Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cardiovascular Drug Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Cardiovascular Drug Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Cardiovascular Drug Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cardiovascular Drug Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Cardiovascular Drug Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Cardiovascular Drug Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Cardiovascular Drug Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Cardiovascular Drug Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Cardiovascular Drug Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Cardiovascular Drug Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Cardiovascular Drug Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Cardiovascular Drug Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Cardiovascular Drug Therapy Sales Value Share by Country, 2025 VS 2032
7 Cardiovascular Drug Therapy Country-level Value Analysis
  1. 7.1 Global Cardiovascular Drug Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cardiovascular Drug Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Cardiovascular Drug Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Cardiovascular Drug Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Cardiovascular Drug Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Cardiovascular Drug Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Cardiovascular Drug Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhejiang Huahai Pharmaceutical
  2. 8.1.1 Zhejiang Huahai Pharmaceutical Company Information
  3. 8.1.2 Zhejiang Huahai Pharmaceutical Business Overview
  4. 8.1.3 Zhejiang Huahai Pharmaceutical Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Zhejiang Huahai Pharmaceutical Cardiovascular Drug Therapy Product Portfolio
  6. 8.1.5 Zhejiang Huahai Pharmaceutical Recent Developments
  7. 8.2 Takeda
  8. 8.2.1 Takeda Company Information
  9. 8.2.2 Takeda Business Overview
  10. 8.2.3 Takeda Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Cardiovascular Drug Therapy Product Portfolio
  12. 8.2.5 Takeda Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Cardiovascular Drug Therapy Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Cardiovascular Drug Therapy Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Qilu pharmaceutical
  26. 8.5.1 Qilu pharmaceutical Company Information
  27. 8.5.2 Qilu pharmaceutical Business Overview
  28. 8.5.3 Qilu pharmaceutical Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Qilu pharmaceutical Cardiovascular Drug Therapy Product Portfolio
  30. 8.5.5 Qilu pharmaceutical Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Cardiovascular Drug Therapy Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Cardiovascular Drug Therapy Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Cardiovascular Drug Therapy Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Gilead
  50. 8.9.1 Gilead Company Information
  51. 8.9.2 Gilead Business Overview
  52. 8.9.3 Gilead Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Gilead Cardiovascular Drug Therapy Product Portfolio
  54. 8.9.5 Gilead Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Cardiovascular Drug Therapy Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Daiichi Sankyo
  62. 8.11.1 Daiichi Sankyo Company Information
  63. 8.11.2 Daiichi Sankyo Business Overview
  64. 8.11.3 Daiichi Sankyo Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Daiichi Sankyo Cardiovascular Drug Therapy Product Portfolio
  66. 8.11.5 Daiichi Sankyo Recent Developments
  67. 8.12 Bayer
  68. 8.12.1 Bayer Company Information
  69. 8.12.2 Bayer Business Overview
  70. 8.12.3 Bayer Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bayer Cardiovascular Drug Therapy Product Portfolio
  72. 8.12.5 Bayer Recent Developments
  73. 8.13 Bristol-Myers
  74. 8.13.1 Bristol-Myers Company Information
  75. 8.13.2 Bristol-Myers Business Overview
  76. 8.13.3 Bristol-Myers Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bristol-Myers Cardiovascular Drug Therapy Product Portfolio
  78. 8.13.5 Bristol-Myers Recent Developments
  79. 8.14 Amgen
  80. 8.14.1 Amgen Company Information
  81. 8.14.2 Amgen Business Overview
  82. 8.14.3 Amgen Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Amgen Cardiovascular Drug Therapy Product Portfolio
  84. 8.14.5 Amgen Recent Developments
  85. 8.15 AstraZeneca
  86. 8.15.1 AstraZeneca Company Information
  87. 8.15.2 AstraZeneca Business Overview
  88. 8.15.3 AstraZeneca Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AstraZeneca Cardiovascular Drug Therapy Product Portfolio
  90. 8.15.5 AstraZeneca Recent Developments
  91. 8.16 United Therapeutics
  92. 8.16.1 United Therapeutics Company Information
  93. 8.16.2 United Therapeutics Business Overview
  94. 8.16.3 United Therapeutics Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  95. 8.16.4 United Therapeutics Cardiovascular Drug Therapy Product Portfolio
  96. 8.16.5 United Therapeutics Recent Developments
  97. 8.17 Tasly Holding Group
  98. 8.17.1 Tasly Holding Group Company Information
  99. 8.17.2 Tasly Holding Group Business Overview
  100. 8.17.3 Tasly Holding Group Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Tasly Holding Group Cardiovascular Drug Therapy Product Portfolio
  102. 8.17.5 Tasly Holding Group Recent Developments
  103. 8.18 Lepu Medical
  104. 8.18.1 Lepu Medical Company Information
  105. 8.18.2 Lepu Medical Business Overview
  106. 8.18.3 Lepu Medical Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Lepu Medical Cardiovascular Drug Therapy Product Portfolio
  108. 8.18.5 Lepu Medical Recent Developments
  109. 8.19 CSPC Pharmaceutical
  110. 8.19.1 CSPC Pharmaceutical Company Information
  111. 8.19.2 CSPC Pharmaceutical Business Overview
  112. 8.19.3 CSPC Pharmaceutical Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  113. 8.19.4 CSPC Pharmaceutical Cardiovascular Drug Therapy Product Portfolio
  114. 8.19.5 CSPC Pharmaceutical Recent Developments
  115. 8.20 CHIA TAI TIANQING
  116. 8.20.1 CHIA TAI TIANQING Company Information
  117. 8.20.2 CHIA TAI TIANQING Business Overview
  118. 8.20.3 CHIA TAI TIANQING Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  119. 8.20.4 CHIA TAI TIANQING Cardiovascular Drug Therapy Product Portfolio
  120. 8.20.5 CHIA TAI TIANQING Recent Developments
  121. 8.21 Boehringer Ingelheim
  122. 8.21.1 Boehringer Ingelheim Company Information
  123. 8.21.2 Boehringer Ingelheim Business Overview
  124. 8.21.3 Boehringer Ingelheim Cardiovascular Drug Therapy Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Boehringer Ingelheim Cardiovascular Drug Therapy Product Portfolio
  126. 8.21.5 Boehringer Ingelheim Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst